Send this to a friend

Farmington's Bioarray gets patent for breast cancer treatment predictive test

Farmington-based molecular diagnostics company Bioarray Genetics Inc. has received a U.S. patent supporting its lead breast cancer predictive test.

The patent covers methods and kits for predicting the effectiveness of breast cancer treatments. The method also generates a report indicating the likelihood of long-term survival with breast cancer recurrence in the patient.

The Bioarray BA100 test will be available to physicians and patients in 2018.

Ide ...

Fields marked in red are required
Your name
Your email
Recipient addresses
(Separate multiple addresses with commas)

Personal message

Copyright 2017 New England Business Media